BR9707776A - Utilização da il-7 no tratamento das doenças autoimunes em especial o diabetes mellitus dependente de insulina - Google Patents

Utilização da il-7 no tratamento das doenças autoimunes em especial o diabetes mellitus dependente de insulina

Info

Publication number
BR9707776A
BR9707776A BR9707776A BR9707776A BR9707776A BR 9707776 A BR9707776 A BR 9707776A BR 9707776 A BR9707776 A BR 9707776A BR 9707776 A BR9707776 A BR 9707776A BR 9707776 A BR9707776 A BR 9707776A
Authority
BR
Brazil
Prior art keywords
treatment
diabetes mellitus
autoimmune diseases
dependent diabetes
especially insulin
Prior art date
Application number
BR9707776A
Other languages
English (en)
Inventor
Jean-Francois Bach
Jean-Marc Gombert
Andre Herbelin
Michel Morre
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR9707776A publication Critical patent/BR9707776A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
BR9707776A 1996-02-28 1997-02-26 Utilização da il-7 no tratamento das doenças autoimunes em especial o diabetes mellitus dependente de insulina BR9707776A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9602501A FR2745185B1 (fr) 1996-02-28 1996-02-28 Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
PCT/FR1997/000343 WO1997031648A1 (fr) 1996-02-28 1997-02-26 Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant

Publications (1)

Publication Number Publication Date
BR9707776A true BR9707776A (pt) 1999-07-27

Family

ID=9489676

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9707776A BR9707776A (pt) 1996-02-28 1997-02-26 Utilização da il-7 no tratamento das doenças autoimunes em especial o diabetes mellitus dependente de insulina

Country Status (13)

Country Link
US (2) US6713053B1 (pt)
EP (1) EP0883406B1 (pt)
JP (1) JP3138481B2 (pt)
AT (1) ATE264112T1 (pt)
AU (1) AU1929397A (pt)
BR (1) BR9707776A (pt)
DE (1) DE69728654T2 (pt)
DK (1) DK0883406T3 (pt)
ES (1) ES2217396T3 (pt)
FR (1) FR2745185B1 (pt)
NO (1) NO321569B1 (pt)
PT (1) PT883406E (pt)
WO (1) WO1997031648A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2745185B1 (fr) * 1996-02-28 1998-05-15 Sanofi Sa Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
CA2772076A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
BR112014014591A8 (pt) 2011-12-12 2017-07-04 Baylor College Medicine processo para a expansão in vitro de células t específicas de antígeno, produto de células t autólogas ou alogênicas expandidas, composição farmacêutica, e, método de tratamento de um paciente, e, usos de uma linhagem de células engenheirada, de células dendríticas pulsadas com misturas de antígeno-peptídeo, de t-apcs pulsadas com misturas de antígeno-peptídeo/peptídeo, e de misturas de antígeno-peptídeo com pbmcs
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP2812431B1 (en) 2012-02-09 2019-07-17 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
JP2016530298A (ja) * 2013-09-05 2016-09-29 サンフォード−バーンハム メディカル リサーチ インスティテュート γδＴ細胞の調節
US11167024B2 (en) 2015-09-18 2021-11-09 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032396A (en) * 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production
US5229115A (en) * 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
US5474769A (en) * 1991-03-08 1995-12-12 Sterling Winthrop Inc. Treatment of microbial infection by monocyte stimulation with interleukin-7
US6576236B1 (en) * 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
FR2745185B1 (fr) * 1996-02-28 1998-05-15 Sanofi Sa Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant

Also Published As

Publication number Publication date
ES2217396T3 (es) 2004-11-01
WO1997031648A1 (fr) 1997-09-04
FR2745185B1 (fr) 1998-05-15
ATE264112T1 (de) 2004-04-15
NO983917L (no) 1998-10-28
JP3138481B2 (ja) 2001-02-26
NO983917D0 (no) 1998-08-26
NO321569B1 (no) 2006-06-06
AU1929397A (en) 1997-09-16
FR2745185A1 (fr) 1997-08-29
DE69728654D1 (de) 2004-05-19
US6713053B1 (en) 2004-03-30
DK0883406T3 (da) 2004-08-02
PT883406E (pt) 2004-08-31
EP0883406B1 (fr) 2004-04-14
DE69728654T2 (de) 2005-03-24
JPH11508605A (ja) 1999-07-27
EP0883406A1 (fr) 1998-12-16
US20040180037A1 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
DE3680368D1 (de) Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate.
BR0011103A (pt) Composição farmacêutica, e, métodos para prevenção ou tratamento de um distúrbio caracterizado por deposição amilóide em um sujeito mamìfero, para determinar o prognóstico de um paciente que está sendo submetido a tratamento de um distúrbio amilóide e para prevenção ou tratamento de uma doença caracterizada por um depósito amilóide em um paciente
ATE111452T1 (de) Tetrahydronaphthalin- und indanderivate, deren herstellung und verwendung für pharmazeutische präparate.
DE69233029D1 (de) Menschliche mesenchym-stammzellen aus dem mark und monoklonale antikörper spezifisch gegen diese zellen
ZA200202942B (en) Elisa for VEGF.
EP1014996A4 (en) PREPARATION OF SACCHARIDES AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSES
DE69636085D1 (de) Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69531098D1 (de) Piperidine und pyrrolidine
FI971420A0 (fi) Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä
WO2005046570A3 (en) Human stem cell materials and methods
DE69841200D1 (de) Oxalate-abbauende mikroorganismen oder oxalate-abbauende enzyme zur verhütung der oxalate-verwandten krankheiten
DE3763851D1 (de) System zur arzneistoffabgabe mit erhoehter bioakzeptanz.
ATE70184T1 (de) Pharmazeutische zusammensetzung zur heilung und verhuetung kardiovaskularer krankheiten und verfahren zu ihrer herstellung.
EP2357223A3 (en) Human stem cell material and methods
PT883406E (pt) Utilizacao da il-7 no tratamento das doencas auto-imunes em particular a diabetes mellitus insulinodependente
ATE199829T1 (de) Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
Friel Familial incidence of Gilles de la Tourette's disease, with observations on aetiology and treatment
DE69534024D1 (de) Peptide und pharmazeutische zusammensetzungen, die diese enthalten
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
TR199901385T2 (xx) Piperidin t�revleri.
MX9803610A (es) Utilizacion de flupirtina para la profilaxis y la terapia de enfermedades que van a compañadas de un deterioro del sistema celular hermatopoyetico.
DE3886950D1 (de) Platin-verbindungen, geeignet zur verwendung als arzneimittel.
DE60135911D1 (de) vERWENDUNG VON SULODEXIDE ZUR BEHANDLUNG VON DIABETISCHER NEPHROPATHIE
AU2459188A (en) Anticoagulative protein pp4-x, and its preparation and use

Legal Events

Date Code Title Description
TE Change of address
PC Transfer

Free format text: SANOFI SYNTHELABO (FR)

EG Technical examination (opinion): publication of technical examination (opinion)
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements